Novartis Halts CAR-T Trials After Three Patient Deaths

Novartis has halted trials of its CD19-directed CAR-T cell therapy after three patients died following a dangerous immune system response, and a similar Bristol Myers Squibb therapy has been placed on hold for a safety review.

Novartis (NVS) has stopped clinical testing of its CD19-directed CAR-T cell therapy after three patients enrolled in company trials died following a dangerous immune system response, and a comparable cell therapy from Bristol Myers Squibb (BMY) has been placed on hold while safety issues are reviewed, according to Endpoints News.

Two halts in the same corner of cell therapy, disclosed at the same time, is the kind of event that reaches beyond the two sponsors involved. CD19 is the most heavily worked target in the entire CAR-T field, and the deaths land in a class of medicine that regulators, investigators and patient groups have spent the past several years arguing about on safety grounds.

What a CD19-directed CAR-T actually does

CAR-T stands for chimeric antigen receptor T-cell therapy. A patient's own T cells — the immune system's serial killers — are collected, genetically re-engineered outside the body to recognize a specific protein on the surface of target cells, then multiplied and infused back. CD19 is a protein carried by B cells. Point an engineered T cell at CD19 and it will hunt B cells, which is why the target has been so productive in B-cell cancers such as leukemia and lymphoma, and why it has since been pushed toward autoimmune disease, where misbehaving B cells are the problem.

The engineering is also the danger. A living drug that expands inside the body can trigger an immune reaction far larger than intended. The field's recognized toxicities include cytokine release syndrome, in which a flood of inflammatory signaling molecules causes fever, low blood pressure and organ stress, and neurological toxicity. These are managed rather than eliminated: patients are treated in certified centers, monitored for weeks and given drugs to damp the reaction down. Deaths attributed to a severe immune response are therefore not unheard of in the class, but three of them inside one sponsor's trial program is enough to stop dosing.

Novartis has not, on the facts available, tied the deaths to anything other than that immune response, and the company has halted the trials rather than continued under amended protocols. The Bristol Myers pause is described as a hold to review safety issues in a similar therapy — the sequencing suggests a read-across judgment about the mechanism rather than a separate cluster of events at Bristol Myers.

Why a second sponsor pausing matters more than the first

When one company stops a trial, the market treats it as a company problem: a manufacturing batch, a protocol, a patient population that was sicker than expected. When a second company pauses a similar therapy in the same window, the question becomes whether the issue belongs to the asset or to the approach.

That distinction determines the cost. If the deaths trace to something specific — a construct design, a conditioning regimen, a dose level, a particular indication — the fix is a protocol amendment and lost months. If investigators and regulators conclude the risk is intrinsic to how this generation of CD19 therapy behaves in the patients being enrolled, the consequences run through eligibility criteria, monitoring requirements, labeling and the economics of treating anyone who is not critically ill.

That last point is the real strategic stake. CAR-T built its case in patients who had exhausted other options, where a serious risk of toxicity is acceptable against a near-certain outcome without treatment. The industry's growth thesis depends on moving earlier in the disease and outward into non-cancer conditions, including autoimmune disease, where patients are less sick and the risk arithmetic is far less forgiving. A safety signal severe enough to halt trials cuts directly against that expansion.

The pipelines and the read-across

For Novartis, cell therapy is one line in a broad portfolio rather than the whole story, which is why a program halt is a pipeline event rather than a company event. The same is true of Bristol Myers, a large-cap pharma with a diversified late-stage book. Neither company's near-term revenue base rests on the trials in question. What is at risk is optionality: the assumption that a validated target can be extended into new indications on a predictable timeline.

The read-across runs wider. Every developer working on CD19 — including smaller, single-asset companies with no other source of value — now has to answer investor questions it did not have to answer last week: what is your rate of severe immune toxicity, how are you monitoring for it, and have you heard from regulators. Companies working through allogeneic or in-vivo approaches will argue their platforms behave differently. That argument becomes easier to make in public and harder to prove in a clinic that has just tightened its enrollment criteria.

Where the shares closed

Both stocks were already at rest when the news circulated. In the most recent session, Novartis last traded at 152.06, down 1.14% from a prior close of 153.81, within a day range of 151.69 to 152.74, as of the market close at 20:00 GMT on Aug. 31, 2026. Bristol Myers Squibb last traded at 66.81, up 0.35% from a prior close of 66.58, having ranged between 65.91 and 67.20. Market data supplied for both listings did not specify the trading currency or exchange.

The broad tape was mixed to slightly lower into that close: the S&P 500 tracker (SPY) ended at $767.05, off 0.30%; the Dow 30 tracker (DIA) at $531.57, down 0.65%; and the Nasdaq 100 tracker (QQQ) at $716.76, up 0.05%. In other words, neither pharma name had yet absorbed a reaction to the halts in the prices above, and the next session is the first clean test of how investors size the damage.

What to watch next

Three things will determine whether this is a delay or a reset. First, whether the U.S. Food and Drug Administration converts the sponsors' voluntary halts into a formal clinical hold, and how broadly it draws the boundary — one asset, one indication, or a class-wide request for information. Second, the causality assessment: whether the deaths are judged related to the therapy, and whether they clustered by dose, by indication or by prior treatment. Third, the resumption terms. A restart with a lower dose, narrower eligibility and mandatory inpatient monitoring is a very different commercial product from what was being tested.

For competitors, the near-term tell is disclosure. Cell therapy developers that volunteer their own safety data and confirm that enrollment continues will separate themselves from those that say nothing. For patients and treating centers, the practical consequence is immediate: trials that were recruiting are not, and the alternatives on offer are the ones that already carry an approval.

Key facts

• NVS last close: 152.06, -1.14%, as of 20:00 GMT Aug. 31, 2026
• BMY last close: 66.81, +0.35%, as of 20:00 GMT Aug. 31, 2026
• Deaths reported: Three patients in Novartis CD19-directed CAR-T trials
• Programs affected: Novartis trials halted; a similar Bristol Myers Squibb therapy on hold

Frequently asked questions

What happened in the Novartis CAR-T trials?

Three patients enrolled in Novartis trials of the company's CD19-directed CAR-T cell therapy died following a dangerous immune system response. Novartis halted the trials. Separately, a similar cell therapy from Bristol Myers Squibb was placed on hold so that safety issues could be reviewed, according to reporting by Endpoints News.

What is a CD19-directed CAR-T therapy?

It is a treatment in which a patient's own T cells are collected, genetically engineered to recognize CD19 — a protein found on the surface of B cells — then grown and infused back. Because the engineered cells attack B cells, the approach has been used in B-cell cancers and is being extended toward autoimmune disease.

Why can CAR-T therapy cause dangerous immune reactions?

CAR-T is a living drug that multiplies inside the body. That expansion can trigger an outsized immune response, including cytokine release syndrome, where a surge of inflammatory signaling molecules causes fever, falling blood pressure and organ stress, and neurological toxicity. These risks are managed with monitoring and suppressive drugs rather than eliminated.

Does the Bristol Myers pause mean its therapy also caused deaths?

That is not what has been reported. The Bristol Myers Squibb program was put on hold to review safety issues in a similar therapy. The sequencing points to a precautionary read-across judgment about the shared mechanism, not a separate set of reported deaths at Bristol Myers.

How did the two stocks trade around the news?

At the most recent close, timed at 20:00 GMT on Aug. 31, 2026, Novartis last traded at 152.06, down 1.14% from a prior close of 153.81. Bristol Myers Squibb last traded at 66.81, up 0.35% from 66.58. The market data supplied did not specify the trading currency or exchange.

What would signal that this is more than a temporary delay?

Watch for a formal FDA clinical hold and how broadly it is drawn, the causality assessment linking the deaths to the therapy or to dose and patient factors, and the terms of any restart. Lower dosing, narrower eligibility and mandatory inpatient monitoring would change the commercial profile substantially.

Sources

• Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused — Endpoints News

Photo: Kampus Production · Pexels Licence — source